Loading
Get Boehringer Ingelheim Cares Foundation Inc
How it works
-
Open form follow the instructions
-
Easily sign the form with your finger
-
Send filled & signed form or save
How to fill out the Boehringer Ingelheim Cares Foundation Inc online
This guide offers a detailed overview of how to complete the Boehringer Ingelheim Cares Foundation Inc application form online. Following these instructions will help ensure that your application is filled out correctly and completely, facilitating the support you may need.
Follow the steps to successfully complete the application form.
- Press the 'Get Form' button to acquire the application form and open it in your preferred editing tool.
- Begin by filling out Section 1, the prescribing healthcare provider information. Ensure all fields are completed. The physician's signature on the attached prescription must match their signature on the application.
- Proceed to Section 2, the patient information section. All fields must be filled out accurately. Where information is not applicable, enter 'N/A' to indicate that the field is intentionally left blank.
- In Section 3, provide detailed financial information. List all sources of current income and attach the required financial documentation. This includes your most recent federal income tax return and any IRS forms that apply.
- Complete Section 4 by addressing all insurance-related questions. If you have applied for the Medicare Part D Low Income Subsidy in the last year and were denied, attach a copy of the denial letter.
- Finally, in Section 5, the patient attestation and signature section, provide your original signature. Ensure that all information provided is complete and accurate to secure eligibility.
- Once you have filled out the entire form, review it for completeness. You can then save your changes, download the application, print it, or share it as necessary.
Start your application process now by completing the Boehringer Ingelheim Cares Foundation Inc form online.
Ridgefield, Conn., December 15, 2021 – Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) has accepted a Biologics License Application (BLA) and granted Priority Review for spesolimab for the treatment of generalized pustular psoriasis (GPP) flares.